• 1
    Morales, A., Eidinger, D. and Bruce, A. W., Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol. 1976. 116: 180183.
  • 2
    Suttmann, H., Riemensberger, J., Bentien, G., Schmaltz, D., Stockle, M., Jocham, D., Bohle, A. and Brandau, S., Neutrophil granulocytes are required for effective bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006. 66: 82508257.
  • 3
    Ludwig, A. T., Moore, J. M., Luo, Y., Chen, X., Saltsgaver, N. A., O'Donnell, M. A. and Griffith, T. S., Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guérin-induced antitumor activity. Cancer Res. 2004. 64: 33863390.
  • 4
    Kemp, T. J., Ludwig, A. T., Earel, J. K., Moore, J. M., Vanoosten, R. L., Moses, B., Leidal, K. et al., Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005. 106: 34743482.
  • 5
    Brandau, S., Suttmann, H., Riemensberger, J., Seitzer, U., Arnold, J., Durek, C., Jocham, D. et al., Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Guérin -activated killer cells. Clin. Cancer Res. 2000. 6: 37293738.
  • 6
    Brandau, S., Riemensberger, J., Jacobsen, M., Kemp, D., Zhao, W., Zhao, X., Jocham, D. et al., NK cells are essential for effective BCG immunotherapy. Int. J. Cancer 2001. 92: 697702.
  • 7
    Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. and Catalona, W. J., T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 1993. 150: 10181023.
  • 8
    Kolls, J. K., Lindén, A., Interleukin-17 family members and inflammation. Immunity 2004. 21: 467476.
  • 9
    Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K., IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009. 27: 485517.
  • 10
    Shibata, K., Yamada, H., Hara, H., Kishihara, K. and Yoshikai, Y., Resident Vdelta1+gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J. Immunol. 2007, 178: 44664472.
  • 11
    Umemura, M., Yahagi, A., Hamada, S., Begum, M. D., Watanabe, H., Kawakami, K., Suda, T. et al., IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guérin infection. J. Immunol. 2007. 178: 37863796.
  • 12
    Takahashi, H., Numasaki, M., Lotze, M. T. and Sasaki, H., Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett. 2005. 98: 189193.
  • 13
    Numasaki, M., Fukushi, J., Ono, M., Narula, S. K., Zavodny, P. J., Kudo, T., Robbins, P. D. et al., Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003. 101: 26202627.
  • 14
    Benchetrit, F., Ciree, A., Vives, V., Warnier, G., Gey, A., Sautes-Fridman, C., Fossiez, F. et al., Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002. 99: 21142121.
  • 15
    Kryczek, I., Wei, S., Szeliga, W., Vatan, L. and Zou, W., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009. 114: 357359.
  • 16
    Hirahara, N., Nio, Y., Sasaki, S., Minari, Y., Takamura, M., Iguchi, C., Dong, M. et al., Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T-cell-dependent tumor-specific immunity in mice. Oncology 2001. 61: 7989.
  • 17
    Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362373.
  • 18
    Silva-Santos, B., Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur. J. Immunol. 2010. 40: 18731876.
  • 19
    Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., Kitamura, H., Nishimura, T., Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 2010. 40: 19271937.
  • 20
    Sutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C. and Mills, K. H., Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009. 31: 331341.
  • 21
    Yuasa, T., Sato, K., Ashihara, E., Takeuchi, M., Maita, S., Tsuchiya, N., Habuchi, T. et al., Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol. Immunother. 2009. 58: 493502.
  • 22
    Kabelitz, D., Wesch, D. and He, W., Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007. 67: 58.
  • 23
    Gunther, J. H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D. and Bohle, A., Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 1999. 59: 28342837.